<document>

<filing_date>
2020-05-28
</filing_date>

<publication_date>
2020-12-03
</publication_date>

<priority_date>
2019-05-31
</priority_date>

<ipc_classes>
C12Q1/6886
</ipc_classes>

<assignee>
UNIVERSAL DIAGNOSTICS, S.L.
</assignee>

<inventors>
MARTINEZ-BAREA, JUAN
BITENC, MARKO
KRUUSMAA, KRISTI
HENSE, CHRISTIAN
CHERSICOLA, Marko
KNAP, Primoz
</inventors>

<docdb_family_id>
70968933
</docdb_family_id>

<title>
DETECTION OF COLORECTAL CANCER
</title>

<abstract>
The present disclosure provides, among other things, methods for colorectal cancer screening and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.
</abstract>

<claims>
1. A in vitro method of screening for colorectal cancer in a subject, the method comprising: a) determining the methylation status of each of the DMR loci in a DMR set as defined in tables 7, 8, 9, 10, 1 1 , 12 or 14, in a subject's DNA sample,
b) comparing the data obtained with reference values obtained from healthy individuals,
c) diagnosing colorectal cancer in the subject if a hyper-methylation in one or more of the loci is detected, as compared to the reference sample.
2. The method of claim 1 wherein the methylation status is determined by methylation specific restriction enzyme quantitative polymerase chain reaction (MSRE-qPCR).
3. The method of any one of claim 2 wherein the DMR loci are amplified by the oligonucleotide primer pairs provided in Table 13.
4. The method of any one of claims 1 to 3, wherein the DNA is isolated from blood, plasma or stool of the human subject.
5. The method of any one of claims 1 to 4, wherein the DNA is cell-free DNA of the human subject.
6. The method of any one of claims 1 to 5, wherein the subject was asymptomatic for colorectal cancer at the time of screening.
7. The method of any one of claims 1 to 18, wherein the subject had been previously screened for colorectal cancer.
8. The method of claim 7, wherein the subject had been screened for colorectal cancer within the last 10 years, within the last 5 years, within the last 4 years, within the last 3 years, within the last 2 years, or within the last year.
9. The method of claim 7 or 8, wherein a previous screen for colorectal cancer in the subject had diagnosed the subject as not having colorectal cancer.
10. The method of claim 9, wherein the previous screen for colorectal cancer that had diagnosed the subject as not having colorectal cancer was within one year.
1 1. The method of claim 9 or 10, wherein the previous screen for colorectal cancer that had diagnosed the subject as not having colorectal cancer was a colonoscopy.
12. The method of any one of claims 1 to 1 1 , wherein the method includes diagnosis of early stage colorectal cancer, optionally wherein the colorectal cancer is a stage 0, stage I, stage IIA, stage MB, or stage IIC colorectal cancer.
13. The method of any one of claims 1 to 12, wherein the method includes diagnosis of early stage colorectal cancer, wherein the cancer has not metastasized.
14. The method of any one of claims 1 to 13, wherein the method provides a sensitivity for colorectal cancer of at least 0.6.
15. The method of claim 14, wherein the method provides a sensitivity for colorectal cancer of at least 0.7.
16. The method of any one of claims 1 to 15, wherein the method provides a specificity of at least 0.7.
17. The method of claim 16, wherein the method provides a specificity of at least 0.8.
18. The method of claim 1 , wherein methylation status is determined using one or more methods selected from the group consisting of methylation sensitive restriction enzyme quantitative polymerase chain reaction (MSRE-qPCR), Methylation-Specific PCR, Methylation Specific Nuclease-assisted Minor-allele Enrichment PCR, and next-generation sequencing.
19. A kit comprising:
(a) primer pairs for the detection of the methylation status of each of the DMR loci in one DMR set as defined in tables 7, 8, 9, 10, 1 1 , 12 or 14 wherein the primers pairs are those of table 13, the kit optionally further comprising:
(b) at least one methylation specific restriction enzyme and/or a bisulfite reagent
(c) a polymerase
20. The method of any one of claims 1 to 18, the diagnosis further comprising determining the presence or absence of an oncogenic mutation.
21. The method of claim 20, wherein the oncogenic mutation is in a gene selected from the group of genes consisting of Kras, NRAS, PIK3CA, PTEN, TP53, BRAF, and APC gene.
22. An in vitro method of screening for colorectal cancer, the method comprising determining the methylation status of one or more colorectal cancer methylation loci selected from:
(a) one or more genes according to Table 1 ; and/or
(b) one or more differentially methylated regions (DMRs) according to Table 7, in DNA of a human subject, and
diagnosing colorectal cancer in the subject.
23. An in vitro method of methylation specific restriction enzyme quantitative polymerase chain reaction (MSRE-qPCR) for colorectal cancer screening, the method comprising:
(a) contacting a sample of DNA of a human subject with one or more methylation specific restriction enzymes; and
(b) performing qPCR of enzyme-digested DNA, or amplicons thereof, to determine the methylation status of one or more colorectal cancer methylation loci selected from:
(i) one or more genes according to Table 1 ; and/or
(ii) one or more differentially methylated regions (DMRs) according to Table 7.
24. The method of any one of claims 22 to23, the method comprising determining whether the one or more methylation loci are hypermethylated as compared to a reference, wherein hypermethylation is indicative of colorectal cancer.
25. The method any one of claims 22 to 24, wherein the method comprises determining the methylation status of at least one DMR of each of ZNF471 and FGF14.
26. The method any one of claims 22 to2 4, wherein the method comprises determining the methylation status of at least one DMR of each of ZNF471 , FGF14, and PDGFD.
27. The method any one of claims 22 to 24, wherein the method comprises determining the methylation status of at least one DMR of each of ZNF471 , FGF14, PDGFD, and ADAMTS2.
28. The method any one of claims 22 to24, wherein the method comprises determining the methylation status of at least one DMR of each of ZNF471 , FGF14, PDGFD, ADAMTS2, ZNF492, ST6GALNAC5.
29. The method any one of claims 22 to 24, wherein the method comprises determining the methylation status of at least one DMR of each of ZNF471 , FGF14, PDGFD, ADAMTS2, ZNF492, ST6GALNAC5, ZNF542, LONRF2, ZNF132, CNRIP1 , and ALK.
30. The method of any one of claims 22 to24, wherein the method comprises determining the methylation status of DMRs ZNF471'558 and FGF14'577.
31. The method of any one of claims 22 to 24, wherein the method comprises determining the methylation status of DMRs ZNF471'558, FGF14'577, and PDGFD'388.
32. The method of any one of claims 22 to 24, wherein the method comprises determining the methylation status of DMRs ZNF471'558, FGF14'577, PDGFD'388, ZNF471'527, and ADAMTS2'284.
33. The method of any one of claims 22 to24, wherein the method comprises determining the methylation status of DMRs ZNF471'558, FGF14'577, PDGFD'388, ZNF471'527, ADAMTS2'284, ADAMTS2'254, ZNF492 Ό69, and ST6GALNAC5'456.
34. The method of any one of claims 22 to 24, wherein the method comprises determining the methylation status of DMRs ZNF471'558, FGF14'577, PDGFD'388, ZNF471'527, ADAMTS2'284, ADAMTS2'254, ZNF492 Ό69, ST6GALNAC5'456, ZNF542 '502, LONRF2'281 , ZNF132'415, PDGFD'921 , ZNF132'268, CNRIP1'272, and ALK'434.
35. The method of any one of claims 22 to 34, wherein one or more of the DMRs are amplified by oligonucleotide primer pairs provided in Table 13.
36. The method of any one of claims 1 to 15, wherein the DNA is isolated from blood, plasma, urine, saliva, or stool of the human subject.
37. The method of any one of claims 22 to 36, wherein the DNA is cell-free DNA of the human subject.
38. The method of any one of claims 22 to 37, wherein the subject was asymptomatic for colorectal cancer at the time of screening.
39. The method of any one of claims 22 to 38, wherein the subject had been previously screened for colorectal cancer.
40. The method of claim 39, wherein the subject had been screened for colorectal cancer with in the last 10 years, within the last 5 years, within the last 4 years, within the last 3 years, within the last 2 years, or within the last year.
41. The method of claim 39 or 40, wherein a previous screen for colorectal cancer in the subject had diagnosed the subject as not having colorectal cancer.
42. The method of claim 41 , wherein the previous screen for colorectal cancer that had diagnosed the subject as not having colorectal cancer was within one year.
43. The method of claim 41 or 42, wherein the previous screen for colorectal cancer that had diagnosed the subject as not having colorectal cancer was a colonoscopy.
44. The method of any one of claims 22 to 43, wherein the method includes diagnosis of early stage colorectal cancer, optionally wherein the colorectal cancer is a stage 0, stage I, stage IIA, stage MB, or stage IIC colorectal cancer.
45. The method of any one of claims 22 to 43, wherein the method includes diagnosis of early stage colorectal cancer, wherein the cancer has not metastasized.
46. The method of any one of claims 22 to 45, wherein the method provides a sensitivity for colorectal cancer of at least 0.6.
47. The method of claim 46, wherein the method provides a sensitivity for colorectal cancer of at least 0.7.
48. The method of any one of claims 22 to 47, wherein the method provides a specificity for colorectal cancer of at least 0.7.
49. The method of claim 48, wherein the method provides a specificity for colorectal cancer of at least 0.8.
50. The method of claim 22, wherein methylation status is determined using one or more members selected from the group consisting of methylation sensitive restriction enzyme quantitative polymerase chain reaction (MSRE-qPCR), Methylation-Specific PCR,
Methylation Specific Nuclease-assisted Minor-allele Enrichment PCR, and next-generation sequencing.
51. A kit for use in colorectal cancer screening, the kit comprising:
(a) at least one oligonucleotide primer pair of Table 13,
the kit optionally further comprising:
(b) at least one methylation specific restriction enzyme and/or a bisulfite reagent.
52. An in vitro diagnostic qPCR reaction for screening of colorectal cancer, the diagnostic qPCR reaction including:
(a) a human DNA sample;
(b) a polymerase; and
(c) at least one oligonucleotide primer pair of Table 13,
optionally wherein the human DNA is bisulfite-treated human DNA or methylation specific restriction enzyme-digested human DNA.
53. The kit or reaction of claim 51 or 52, wherein the oligonucleotide primer pairs include oligonucleotide primer pairs for amplification of DMRs ZNF471'558 and FGF14'577.
54. The kit or reaction of claim 51 or 52, wherein the oligonucleotide primer pairs include oligonucleotide primer pairs for amplification of DMRs ZNF471'558, FGF14'577, and PDGFD'388.
55. The kit or reaction of claim 51 or 52, wherein the oligonucleotide primer pairs include oligonucleotide primer pairs for amplification of DMRs ZNF471'558, FGF14'577, PDGFD '388, ZNF471'527, and ADAMTS2'284.
56. The kit or reaction of claim 51 or 52, wherein the oligonucleotide primer pairs include oligonucleotide primer pairs for amplification of DMRs ZNF471'558, FGF14'577, PDGFD '388, ZNF471'527, ADAMTS2'284, ADAMTS2'254, ZNF492 Ό69, and ST6GALNAC5'456.
57. The kit or reaction of claim 51 or 52, wherein the oligonucleotide primer pairs include oligonucleotide primer pairs for amplification of DMRs ZNF471'558, FGF14'577, PDGFD '388, ZNF471'527, ADAMTS2'284, ADAMTS2'254, ZNF492 Ό69, ST6GALNAC5'456, ZNF542'502, LONRF2'281 , ZNF132'415, PDGFD'921 , ZNF132'268, CNRIP1'272, and ALK'434.
58. The kit or reaction of any one of claims 22 to 50, further comprising using the determined methylation status of the one or more methylation loci to identify at least one of (i) to (iv) as follows: (i) a presence of colorectal cancer in the human subject; (ii) a predisposition for colorectal cancer in the human subject; (iii) an increased risk of colorectal cancer in the human subject, and (iv) a stage of colorectal cancer in the human subject.
59. The method of any one of claims 22 to 50, the diagnosis further comprising determining the presence or absence of an oncogenic mutation.
60. The method of claim 59, wherein the oncogenic mutation is in a gene selected from the group of genes consisting of Kras, NRAS, PIK3CA, PTEN, TP53, BRAF, and APC gene.
61. The method of any one of claims 22 to 50, wherein the method is an in vitro method.
</claims>
</document>
